With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.81237-69-6,5-Bromo-1,2,3,4-tetrahydroisoquinoline,as a common compound, the synthetic route is as follows.,81237-69-6
o a solution of 5-bromo-1,2,3,4-tetrahydroisoquinoline (1.0 g, 4.72 mmol) in ethylene glycol (15mL) was added copper(I) iodide (898 mg, 4.72 mmol), K3P04 (3.0 g, 14.15 mmol) and 4-iodo-1-methyl-1H-pyrazole (1.96 g, 9.43 mmol). The reaction mixture was heated to 120 C for 3 hunder a nitrogen atmosphere. After cooling to room temperature, the mixture was filtered andconcentrated in vacuo. Water (50 mL) was added and extracted with DCM (30 mL x 3). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude residue was purified by silica gel chromatography (petroleum ether / EtOAc = 1: 1) to give the title compound (0.28 g, 42% purity) as a brown solid which was further purifiedby reverse phase chromatography (acetonitrile 5-35/0.05% HC1 in water) to give the titlecompound (0.05 g, 4%, HC1 salt) as a light yellow solid. ?H NMR (400 IVIFIz, DMSO-d6) 9.77(s, 1H), 8.65 (s, 1H), 8.26 (s, 1H), 8.11 (d, J 8.0 Hz, 1H), 7.99 (d, J 7.2 Hz, 1H), 7.60-7.54(m, 1H), 4.55 (t, J= 8.0 Hz, 2H), 3.95 (s, 3H), 3.38 (t, J= 8.0 Hz, 2H), 2.54 (s, 2H). LCMS M/Z(M+H) 292.
The synthetic route of 81237-69-6 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC.; CYR, Patrick; BRONNER, Sarah; ROMERO, F. Anthony; MAGNUSON, Steven; TSUI, Vickie Hsiao-Wei; MURRAY, Jeremy M.; WAI, John; LAI, Kwong Wah; WANG, Fei; CHEN, Kevin X.; (351 pag.)WO2017/205538; (2017); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem